Development of HIV Vaccine Can End The HIV/AIDS Pandemic

Currently, HIV treatment and prevention methods are not effective in eliminating the infection. Hence, development of HIV vaccine is necessary to end the HIV/AIDS pandemic.

HIV treatment and prevention methods that are currently available are not sufficient to reduce the HIV infection. Therefore, there is an increased need for an effective HIV vaccine that can curb the disease, reveals a new study.

The new //commentary was from Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Feuding Antibodies Blocked High-profile HIV Vaccine Trial
A high-profile HIV vaccine trial that was shown to work in just under a third of patients may have been hindered by feuding antibodies, says US researchers.

‘There is an urgent need to develop an effective HIV vaccine and also to increase the use of current treatment and prevention tools.’

Theoretically, effective global implementation of existing HIV treatment and prevention tools could end the HIV/AIDS pandemic. Antiretroviral therapy that suppresses HIV both benefits the health of those living with HIV and prevents viral transmission to their HIV-negative sexual partners.

Additionally, strategies such as pre-exposure prophylaxis (PrEP) can effectively prevent HIV acquisition among people at high risk for infection.

However, from a practical standpoint, ending the HIV/AIDS pandemic without a vaccine is unlikely. Despite extraordinary progress in implementing HIV testing and treatment, substantial gaps remain.

Complex Protein may Help HIV Vaccine Development
Scientists at Duke University have taken aim at what may be an Achilles' heel of the HIV virus.

Globally, more than 17 million people living with HIV are not receiving antiretroviral therapy. This is compounded by the continuing high rate of new infections, an estimated 1.8 million worldwide in 2016 alone.

Modeling studies have suggested that the wide geographic dispersion of people, especially in certain rural areas, would make it extremely difficult to reach all those who need HIV treatment and prevention services.

In Infants, HIV Vaccines Elicit Immune Response
A new analysis of two HIV vaccine trials that involved pediatric patients shows that the investigational vaccines stimulated a critical immune response in infants born to HIV-infected mothers.

In addition, the economic resources needed to leverage HIV treatment and prevention across the globe continually increase as people become newly infected.

Dr. Fauci writes that even a modestly effective HIV vaccine could substantially slow the pandemic, if deployed alongside current treatment and prevention efforts. Because the immune system mounts an inadequate protective response against HIV, an HIV vaccine most likely will not be as effective as proven vaccines used to control or end global outbreaks, such as yellow fever and polio vaccines, which are nearly 100 percent effective.

Experimental HIV Vaccine Candidate may Generate Immune Response to Block Infection
An experimental vaccine that contains a special class of immune system molecules may have the potential to stimulate the immune system to block HIV infection.

According to modeling studies, if current HIV treatment and prevention efforts are sustained and an HIV vaccine that is at least 50 percent effective is developed and deployed, the pandemic could be curbed.

It is critical to continue and accelerate a robust research effort to develop an HIV vaccine that is at least moderately effective, while also aggressively scaling up the implementation of current treatment and prevention tools, Dr. Fauci concludes.

Source-Eurekalert